About
Partners
Axis Therapeutics is a joint venture established in 2018 between Athenex, Inc. (NASDAQ:ATNX) and Xiangxue Life Sciences Limited, a subsidiary of Xiangxue Pharmaceutical Co., Ltd (Shenzhen Exchange:300147).
​
Axis Therapeutics in-licensed the worldwide rights (excluding mainland China) for the research, development and commercialization of T cell receptor-engineered T cells (TCR-T), a technology based on the TAEST (TCR Affinity Enhanced Specific T cell therapy) platform from Xiangxue Life Sciences. Xiangxue Life Sciences retains the rights to mainland China for the technology.
​
